Medical education review • Updated 10 November 2026. Not a substitute for individualized clinical assessment and local prescribing guidance.
Introduction and classification
Hormonal contraceptive medicines are classified as combined estrogen–progestin preparations and progestin-only methods. Their effectiveness depends on endocrine suppression, local reproductive-tract effects, formulation and correct use. Contraceptive prescribing additionally requires the CDC U.S. MEC and selected practice recommendations [1–3].
Active ingredients and structures
Combined formulations may contain ethinyl estradiol, estradiol or ester-based estrogen components together with a progestin. Common progestins include levonorgestrel, norethindrone, desogestrel, etonogestrel and drospirenone. Norethindrone and levonorgestrel are 19-nortestosterone derivatives; drospirenone is structurally related to spironolactone and has antimineralocorticoid activity. Ethinyl estradiol contains a 17α-ethynyl substituent, not a vinyl group. Chemical ancestry alone does not determine effectiveness or adverse-event risk [1].
Mechanisms of action
Combined estrogen–progestin methods suppress gonadotropin secretion, especially the mid-cycle LH surge, preventing ovulation. The progestin additionally thickens cervical mucus and causes endometrial changes. Progestin-only implants and many pills suppress ovulation; traditional norethindrone pills have a greater reliance on cervical-mucus effects and may permit ovulation in some cycles. Levonorgestrel IUDs act predominantly through local cervical-mucus/endometrial changes; many users continue to ovulate. DMPA suppresses ovulation through sustained progestin exposure [1,3].
Routes and pharmacokinetics
Oral pills undergo absorption and variable hepatic metabolism; vomiting, severe diarrhea and potent enzyme-inducing drugs may compromise selected preparations. Transdermal patches and vaginal rings avoid daily oral administration but still expose users systemically to estrogen/progestin. Depot injectables release medroxyprogesterone slowly, implants release etonogestrel continuously and levonorgestrel IUDs act largely locally, although systemic exposure still occurs [1].
Emergency contraception and mechanisms
Levonorgestrel emergency contraception principally delays or inhibits ovulation and is most effective soon after intercourse; ulipristal acetate is a selective progesterone-receptor modulator and can delay follicular rupture closer to the LH surge. A copper IUD is a highly effective nonhormonal emergency method. Oral emergency contraception is not an abortifacient and does not terminate an established pregnancy. Following ulipristal, starting progestin-containing contraception too soon can reduce efficacy; follow CDC timing guidance [3].
Risks and benefits
CHCs can improve heavy or painful periods, acne and cycle predictability but carry estrogen-related thrombosis risk. Progestin-only methods avoid estrogen exposure, but irregular bleeding is common. Interactions and eligibility vary among methods; use individual product labeling and CDC classifications rather than claiming all hormonal options share the same safety profile [2,3].
Clinical takeaway
Hormonal contraception is not a single pharmacologic entity. Match the molecular mechanism and delivery system to the patient and distinguish IUDs, emergency contraception and menstrual-hormone therapy carefully.
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. Available from: https://www.cdc.gov/contraception/hcp/usmec/
- Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. Available from: https://www.cdc.gov/contraception/hcp/usspr/
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.